Prolocor
Company

Prolocor

Biotechnology Research Philadelphia, Pa, United States 7 employees
Employees
7
Contacts
2
Emails
2

Prolocor Overview

Headquarters
Philadelphia, Pa, United States
Industry
Biotechnology Research
Employees
7
Founded
2020
Funding
1.7M
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)

About Prolocor

There are 50 million people living with chronic coronary artery disease in the U.S., Europe, and Japan. Of these, over 2 million suffer from acute coronary syndrome every year. In each case, the doctor and patient must decide whether to use more powerful therapy to prevent thrombosis – increasing the risk of bleeding – or less intensive therapy – reducing bleeding risk at the expense of more thrombotic events such as heart attack, stroke, and cardiovascular death. Prolocor’s precision tool will guide treatment decisions, effectively matching the intensity of therapy with the risk of events. Founded by a team that deeply understands thrombosis and cardiovascular disease, Prolocor is building its strategy around platelet FcγRIIa and embarking on a journey to commercialize an innovative precision diagnostic test that quantifies FcγRIIa on the surface of platelets.

Prolocor Contact Details

People in AeroLeads
4
With contact data
2
Email contacts
2
50.0% coverage

Prolocor Org Chart

Sample employees and titles
Name Title Contact
Jameson Hill Laboratory Technologist at Prolocor Biological Science Graduate from Csu
View
David Schneider Chief Scientific Officer and Co-founder at Prolocor
Email
Peter Hoehn Life Sciences Executive - Commercial Leader in Diagnostics, Pharma and Digital - Precision Medicine Strategy and Commercialization Expertise
Email
Westen Hahn Biotech and Laboratory Professional, Clia Lab General Supervisor
View

Employees by Management Level

Individual contributor 3 profiles
Executive 1 profile

Compare Similar Companies to Prolocor